Abeona Therapeutics Inc.

Stock market turmoil due to macroeconomic uncertainty and biopharmaceutical industry-specific concerns have made it more difficult for publicly traded drug developers to pursue follow-on public offeri

The regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu

Abeona Therapeutics obtained US Food and Drug Administration approval on 29 April for Zevaskyn, an autologous cell-based gene therapy for the ultra-rare connective tissue disorder recessive dystrophic

“Pipeline in a pill”-style drug development will be on display in April, when more than half of the user fee goal dates are for new indications on sometimes sprawling labels, as well as one novel biol